Yield from innovation
Our approach allows investors to access product-level, contractual cash flows that aren’t uncorrelated to public market performance. Our transactions are sourced and structured by a specialized life- sciences team with deep domain expertise across pricing, reimbursement, launch, and commercialization.
Ask us a question
Learn more
Tied to products, not to markets
Severan accelerates liquidity, offering a shorter and more predictable return horizon of 3–7 years tied to commercial revenue and capped payout.
Ask us a question
Learn more
Structure as safeguard
We negotiate terms directly with the companies and design each investment vehicle to safeguard investor capital. Capital disbursement is gated on milestones such as performance relative to forecast targets. We manage binary clinical or regulatory risk.
Ask us a question
Learn more
Selective by design
Our investor syndicate includes family offices and high-net-worth individuals, institutional allocators, and strategic investors seeking exposure to biomedical commercial revenue. Investors may participate on a deal-by-deal basis or in aggregate across financings.
Ask us a question
Learn more
